Compare Biogen Inc (BIIB) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs United States Natural Gas Fund — how do they compare? Biogen Inc trades at $194.08 (market cap $28.34B), while United States Natural Gas Fund trades at $10.5. The key difference: Biogen Inc is trading nearer its 52-week high, United States Natural Gas Fund nearer its low. Which is the better fit depends on your goals.
| BIIB | UNG | |
|---|---|---|
Market Cap | $28.34B | — |
Sector | Health | Commodities - Energy |
52-Week High | $216.63 | $16.90 |
52-Week Low | $122.68 | $10.15 |
Enterprise Value | $30.62B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
UNG trades at $10.37, down 2.17% today, with a bearish technical signal from moving averages. The fund tracks natural gas futures, facing headwinds from contango effects and weather-dependent demand. Recent news highlights volatility tied to LNG exports and storage data, with EIA forecasting record 2026 supply and demand (Reuters, 2026-06-09).
Outlook remains cautious due to structural challenges in futures roll costs and price sensitivity to weather. Risks include production swings and geopolitical factors, while opportunities hinge on sustained LNG demand growth. Long-term performance has been hampered by contango, as noted by 24/7 Wall Street (2026-05-28).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
